BioNTech
BNTX
|
NASDAQ
|
17 Followers
Fair Price
$21.17
Overvalued by 83.7%
To display the fair price of a share, you need to be a member of Bulios Black.
Company Quality
Dividends
Earnings
My Notes
You haven't added any notes for this stock yet. Use this space to record your insights or strategies.
Profile
Key Metrics TTM
Performance
Earnings Waterfall
Debt level and coverage
Earnings
Feed
Read More
Today, BioNTech $BNTX-2.6% reported quarterly results, which currently focuses on, for example, the development and research of drugs aimed at treating cancer and infectious diseases. Q2 2023 earnings were in the red, with the company reporting a loss of -190.4 million, compared to a profit of 1.7 billion in Q2 2022. The company has invested heavily in R&D this year, so hopefully...
Read more
Read More
Have a great Monday,
do you have a healthcare sector represented?
I have $CVS-0.8% so far, the stock is down a lot at the moment, so I'm thinking of overbought. Long term then I follow $BNTX and now more recently $TNYA-1.6%, which has become my heartthrob (they deal with heart defect treatments).
Zobrazit další komentáře
Healthcare is not represented at all... I honestly don't even know what to look for in it, I don't know any companies and I don't even have anyone around to ask in that regard :) It's a bit of a blackbox for me.
>2y
Read More
BioNTech $BNTX
BioNTech reported its results yesterday.
This company focuses and specializes in the development and research of immunotherapeutic drugs targeting the treatment of cancer and infectious diseases.
It is also known for the development and production of the COVID-19 vaccine with Pfizer.
Results for the first quarter of this year :
Revenues : EUR 1.28 billion, first...
Read more
Zobrazit další komentáře
I would strongly consider $PFE-3.8%, but I already have healthcare represented in my portfolio, so I don't want to overdo it($CVS-0.8%).
As has been written here, the drop in sales is really big, but it's probably really just because of the covid.